NCT00118638View on ClinicalTrials.gov

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

705

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

January 31, 2005

Conditions
AnemiaNon-Myeloid Malignancies
Interventions
DRUG

Darbepoetin alfa - 2.25 mcg/kg

Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W

DRUG

Darbepoetin alfa - 500mcg

Darbepoetin alfa 500mcg Q3W dosing / placebo QW

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY